Brief: Biomarin Pharmaceutical Inc - Discontinues Phase 2 Voxzogo Trials In Turner Syndrome, Shox-Deficiency, Acan-Deficiency - SEC Filing
16/03/2026 12:38
March 16 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O: BIOMARIN PHARMACEUTICAL INC - DISCONTINUES PHASE 2 VOXZOGO TRIALS IN TURNER SYNDROME, SHOX-DEFICIENCY, ACAN-DEFICIENCY - SEC FILING BIOMARIN: DECISION TO DISCONTINUE FOLLOWING OCCURRENCE OF SEVERAL SLIPPED CAPITAL FEMORAL EPIPHYSIS EVENTS IN 2 ONGOING INVESTIGATOR-SPONSORED TRIALS BIOMARIN PHARMACEUTICAL - PHASE 2 CANOPY TRIALS OF VOXZOGO IN NOONAN SYNDROME, IDIOPATHIC SHORT STATURE TO CONTINUE - SEC FILING Source text: [] Further company coverage: BMRN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife